Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial | Synapse
March 3, 2026Open Access
Safety and pharmacokinetics of sulfasalazine and its metabolite sulfapyridine for treatment of preterm preeclampsia in Australia (SIP): an early phase, unblinded, single-arm, proof of concept clinical trial
Key Points
Sulfasalazine shows promising effects on safety in preterm preeclampsia treatment, indicating potential benefits.
The pharmacokinetics of sulfasalazine were closely monitored, revealing important absorption characteristics.
Single-arm trial assessed both safety and efficacy indicators in a specifically targeted group of patients.
This could lead to new therapeutic options for preterm preeclampsia, emphasizing the need for further validation.